Unichem Laboratories Limited
Valuation (100/100) does the heavy lifting; financial trend (8/100) is the drag.
Buy zoneOur blended model reads Unichem Laboratories Limited as a Buy at 64/100. We put fair value near ₹1,026.8; at ₹513.4 that leaves roughly 100% upside, so the stock screens undervalued by 100%. On 12.1x trailing earnings it sits cheaper than the Healthcare median of about 37.6x. The price is about 21% below its 52-week high of ₹650.6 and 81% above the low of ₹284.05. Financial health scores 59/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9. It clears 8 of 13 investability checks, with durability 48, valuation 100 and momentum 88 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹821.44. Low-confidence estimate — limited data.
1-year price
EOD · 2026-07-3152-week range
-21.09% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Buy64Piotroski F-score 5/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 9.8%
- Pass: Low debt (D/E < 0.5): 0.18x
- Fail: Positive free cash flow
- Fail: Revenue growth > 10%: -2%
- Fail: Earnings growing: -79%
- Pass: Net margin ≥ 10%: 11.2%
- Pass: Current ratio > 1.5: 2.48
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 3.36
- Fail: Piotroski ≥ 7: 5/9
Quarterly results
Annual financials
Shareholding
- Promoter71.3%
- Institutions9.8%
- Public & other18.9%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 3.36.
Opportunities
- Trading in our value buy zone versus sector peers.
- Trades ~100% below our estimated fair value.
Bear case
Threats
- Earnings contracting year on year.
About Unichem Laboratories Limited
Unichem Laboratories manufactures and distributes pharmaceutical products across India, the United States, and international markets. Its portfolio includes formulations spanning gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective, and pain management, alongside active pharmaceutical ingredients and contract manufacturing services.
Unichem Laboratories Limited — frequently asked questions
Is Unichem Laboratories Limited a buy, hold or sell?
StocksWizard currently rates Unichem Laboratories Limited (UNICHEMLAB) a Buy, based on a blended score of 64/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Unichem Laboratories Limited's fair value?
Our blended DCF and relative-valuation model estimates Unichem Laboratories Limited's fair value at about ₹1,026.8, versus a current price of ₹513.4 — roughly 100% upside. On that basis the stock looks undervalued by 100%.
Is Unichem Laboratories Limited financially healthy?
Unichem Laboratories Limited scores 59/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9.
How has Unichem Laboratories Limited's share price performed?
Unichem Laboratories Limited is up 36% over three months, and last traded at ₹513.4. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.